Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
June 2022 in “Zenodo (CERN European Organization for Nuclear Research)” The hydrogel with neem and tridax extracts effectively treats seborrheic dermatitis.
January 2020 in “Dépôt Institutionnel de lUniversité de Tlemcen” November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
September 2024 in “Journal of the American Academy of Dermatology” Hair loss significantly affects the quality of life for Muslim American women, especially those not wearing hijab.
1 citations
,
April 2023 in “Preprints.org” SEFFI is a safe and effective anti-aging treatment with few complications.
12 citations
,
August 2018 in “Psychiatry research” Estazolam reduces anxiety-like behavior in PTSD by increasing allopregnanolone levels.
3 citations
,
March 2023 in “JAAD case reports” Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
October 2012 in “The American Journal of Gastroenterology” A hairball in the stomach can cause serious issues and may need surgery and psychiatric care.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
1 citations
,
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” The document outlines a plan to test if certain methods can prevent developmental delays in children at Pakistani public healthcare centers.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
March 2017 in “Drug delivery letters” Dr. Jia-You Fang is a highly experienced researcher in drug delivery and related fields, with numerous publications and international collaborations.
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
6 citations
,
January 2011 in “Journal of pediatric endocrinology & metabolism/Journal of pediatric endocrinology and metabolism” An 11-year-old Greek girl was diagnosed with a rare genetic disorder, highlighting the importance of genetic testing and family history.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
June 2019 in “Journal of Aesthetic Nursing” The author now supports the JCCP's efforts to improve non-surgical aesthetic practices after initial skepticism.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
July 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” A new Wnt surrogate specifically targets the Frizzled7 receptor, promoting organoid formation and hair growth.
February 2026 in “Biomaterials” BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.
January 2024 in “Faculty of 1000 Research Ltd” Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.
Researchers made new compounds that could potentially be developed into anticancer drugs.
May 2018 in “Dermatologic Surgery”
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.